Exubera Lung Test Will Be Advised Until More Data Is Collected, FDA Says
Executive Summary
A recommendation for patients taking Pfizer's Exubera to get lung function tests every six to 12 months will continue until the agency has more information on the product's effect on the lungs from post-marketing studies
You may also be interested in...
MannKind’s Long, Winding Development Road Ends In Approval Of Afrezza Inhaled Insulin
Firm now faces the commercial gauntlet of establishing an inhaled insulin in the crowded diabetes market.
Ghosts of Exubera Haunt Afrezza As Lung Function, Cancer Concerns Weigh Heavily
FDA advisory committee review of MannKind’s inhaled insulin revisits safety issues that troubled Pfizer’s first-of-its-kind product, including a potential lung cancer risk and declines in pulmonary function.
Lilly Diabetes Sales Growth Slows; Newer Products Take The Lead
Despite efforts to strengthen its position in the diabetes market, revenue from Lilly's diabetes care franchise - Humulin, Humalog, Actos and Byetta - increased just 5% to $701.7 mil. in the second quarter, primarily on the strength of Byetta